So if the results point towards readily manageable CHF, improved ejection fractions etc, plus a clear difference in adverse events at 12 months, reduced hospitalisation etc that were not there in the 2a trial at 1/6 the dose, where would the SP land?
I would expect at least some of the above otherwise why bother accepting such a late report to the conference. Something in there that could point to a change in accepted clinical practice.
- Forums
- ASX - By Stock
- MSB
- All Aboard
All Aboard, page-4
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.08 |
Change
0.050(4.85%) |
Mkt cap ! $1.230B |
Open | High | Low | Value | Volume |
$1.05 | $1.09 | $1.03 | $4.130M | 3.870M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 18508 | $1.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.08 | 50253 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 18508 | 1.075 |
23 | 44694 | 1.070 |
8 | 36051 | 1.065 |
9 | 37713 | 1.060 |
3 | 23555 | 1.055 |
Price($) | Vol. | No. |
---|---|---|
1.080 | 50253 | 16 |
1.085 | 123599 | 15 |
1.090 | 224479 | 11 |
1.095 | 108131 | 10 |
1.100 | 248633 | 23 |
Last trade - 13.07pm 02/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |